Netarsudil significantly reduces intraocular pressure in patients

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic

Safety and efficacy of ripasudil in Japanese patients with

PDF) A multicenter, open-label study of netarsudil for the

Netarsudil Effects on Mean Diurnal Intraocular Pressure Relative

CAS 1422144-42-0 Netarsudil Mesylate - BOC Sciences

Pharmaceuticals, Free Full-Text

Lowering IOP: Will First-Line Options Change?

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic

An overview of new glaucoma medications - EyeWorld

Netarsudil effect on IOP in a dose-dependent manner both with and

FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug

Discovery and Preclinical Development of Netarsudil, a Novel

Newly Approved Glaucoma Drugs Greatly Reduce Eye Pressure

Identification of Nitric Oxide-Donating Ripasudil Derivatives with

Discovery and Preclinical Development of Netarsudil, a Novel